Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
BackgroundAdjuvant chemotherapy and targeted therapy have become standard postoperative therapeutic modalities for human epidermal growth factor receptor 2 (HER2)-positive breast cancer(HER2-positive,HR-negative), including triple-positive breast cancer(HER2-positive,HR-positive). However, these two...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.999894/full |
| _version_ | 1828063140548444160 |
|---|---|
| author | Dongxu Ma Qing Yang Ke Yin Peng Shi Xiao Chen Tianyi Dong Xingchen Shang Xingchen Shang Xingsong Tian Xingsong Tian |
| author_facet | Dongxu Ma Qing Yang Ke Yin Peng Shi Xiao Chen Tianyi Dong Xingchen Shang Xingchen Shang Xingsong Tian Xingsong Tian |
| author_sort | Dongxu Ma |
| collection | DOAJ |
| description | BackgroundAdjuvant chemotherapy and targeted therapy have become standard postoperative therapeutic modalities for human epidermal growth factor receptor 2 (HER2)-positive breast cancer(HER2-positive,HR-negative), including triple-positive breast cancer(HER2-positive,HR-positive). However, these two types of breast cancer differ in terms of pathogenesis. This article analyzes these two types of breast cancer by comparing their prognoses.MethodsThe clinicopathological characteristics of 135 patients, including 60 patients with triple-positive breast cancer and 75 patients with HER2-positive breast cancer, were analyzed to compare the disease-free survival (DFS) and overall survival (OS) of the two groups over a 5-year period. A multifactorial Cox risk model was constructed by grouping age, menstrual status, maximum tumor diameter, number of lymph node metastases, pathological staging, and Ki-67 staining results. All statistical data were analyzed in detail using SPSS25.0 statistical software.ResultsThe 5-year OS rates of patients with breast cancer in the triple-positive and HER2-positive groups were 96.7% and 82.7%, respectively, and the 5-year DFS rates were 90% and 73.3%, respectively. The Cox results revealed that molecular staging was an independent factor affecting recurrent metastasis and survival of breast cancer patients (hazard ratio [HR] =2.199, 95% confidence interval [CI], 1.296-8.266; HR = 9.994, 95% CI, 2.019-49.465).ConclusionThe 5-year DFS and OS rates were significantly better in the triple-positive group than in the HER2-positive group. Subgroups received different prognosis for different chemotherapy regimens. Breast cancer patients should be treated according to the risk of recurrence with symptomatic treatment and precise regulation. |
| first_indexed | 2024-04-10T22:39:35Z |
| format | Article |
| id | doaj.art-752a310c772d470d8d4e5bfa014f7e24 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T22:39:35Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-752a310c772d470d8d4e5bfa014f7e242023-01-16T08:56:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.999894999894Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective studyDongxu Ma0Qing Yang1Ke Yin2Peng Shi3Xiao Chen4Tianyi Dong5Xingchen Shang6Xingchen Shang7Xingsong Tian8Xingsong Tian9Department of Breast and Thyroid surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Pathology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, ChinaDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, ChinaBackgroundAdjuvant chemotherapy and targeted therapy have become standard postoperative therapeutic modalities for human epidermal growth factor receptor 2 (HER2)-positive breast cancer(HER2-positive,HR-negative), including triple-positive breast cancer(HER2-positive,HR-positive). However, these two types of breast cancer differ in terms of pathogenesis. This article analyzes these two types of breast cancer by comparing their prognoses.MethodsThe clinicopathological characteristics of 135 patients, including 60 patients with triple-positive breast cancer and 75 patients with HER2-positive breast cancer, were analyzed to compare the disease-free survival (DFS) and overall survival (OS) of the two groups over a 5-year period. A multifactorial Cox risk model was constructed by grouping age, menstrual status, maximum tumor diameter, number of lymph node metastases, pathological staging, and Ki-67 staining results. All statistical data were analyzed in detail using SPSS25.0 statistical software.ResultsThe 5-year OS rates of patients with breast cancer in the triple-positive and HER2-positive groups were 96.7% and 82.7%, respectively, and the 5-year DFS rates were 90% and 73.3%, respectively. The Cox results revealed that molecular staging was an independent factor affecting recurrent metastasis and survival of breast cancer patients (hazard ratio [HR] =2.199, 95% confidence interval [CI], 1.296-8.266; HR = 9.994, 95% CI, 2.019-49.465).ConclusionThe 5-year DFS and OS rates were significantly better in the triple-positive group than in the HER2-positive group. Subgroups received different prognosis for different chemotherapy regimens. Breast cancer patients should be treated according to the risk of recurrence with symptomatic treatment and precise regulation.https://www.frontiersin.org/articles/10.3389/fonc.2022.999894/fulltriple-positive breast cancerHER2-positive breast cancerclinicopathological characteristicsprognosishormone receptorsadjuvant chemotherapy |
| spellingShingle | Dongxu Ma Qing Yang Ke Yin Peng Shi Xiao Chen Tianyi Dong Xingchen Shang Xingchen Shang Xingsong Tian Xingsong Tian Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study Frontiers in Oncology triple-positive breast cancer HER2-positive breast cancer clinicopathological characteristics prognosis hormone receptors adjuvant chemotherapy |
| title | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study |
| title_full | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study |
| title_fullStr | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study |
| title_full_unstemmed | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study |
| title_short | Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study |
| title_sort | analysis of the clinicopathological characteristics and prognosis of triple positive breast cancer and her2 positive breast cancer a retrospective study |
| topic | triple-positive breast cancer HER2-positive breast cancer clinicopathological characteristics prognosis hormone receptors adjuvant chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.999894/full |
| work_keys_str_mv | AT dongxuma analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT qingyang analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT keyin analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT pengshi analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT xiaochen analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT tianyidong analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT xingchenshang analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT xingchenshang analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT xingsongtian analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy AT xingsongtian analysisoftheclinicopathologicalcharacteristicsandprognosisoftriplepositivebreastcancerandher2positivebreastcanceraretrospectivestudy |